Iron chelators as drugs against malaria pose a potential risk

Redox Report

Volumn 8, Issue 5, 2003, Pages 268-271

  Golenser, Jacob ^a   Domb, Abraham ^a   Leshem, Benny ^b   Kremsner, Peter ^c   Luty, Adrian ^c  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b The Mnistry of Health   (Israel)

^c Institute of Tropical Medicine   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DEFEROXAMINE; IRON CHELATING AGENT; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE;

ANTIMALARIAL ACTIVITY; ARTICLE; CYTOKINE PRODUCTION; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; HEARING IMPAIRMENT; HUMAN; LIVER FIBROSIS; MALARIA; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; SENSORY DYSFUNCTION; VISUAL IMPAIRMENT;

ANIMALS; HUMANS; IRON; IRON CHELATING AGENTS; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; RISK FACTORS;

EID: 0347028454     PISSN: 13510002     EISSN: None     Source Type: Journal    
DOI: 10.1179/135100003225002880     Document Type: Article

References (29)

1. Loyevsky M, Gordeuk VR. Iron chelators. In: Rosenthal PJ. (ed) Antimalarial Chemotherapy. Totowa, New Jersey: Humana, 2001; 307-324.
2. Le NTV, Richardson DR. The role of iron in cell cycle progression and the proliferation of neoplastic cells. Biochim Biophys Acta 2002; 1603: 31-46.
3. Nappi AJ, Vass E. Interactions of iron with reactive intermediates of oxygen and nitrogen. Dev Neurosci 2002; 24: 134-142.
4. Greene BT, Thorburn J, Willingham MC et al. Activation of caspase pathways during iron chelator-mediated apoptosis. J Biol Chem 2002; 277: 25568-25575.
5. Cabantchik ZI, Glickstein H, Golenser J, Loyevsky M, Tsafack A. Iron chelators: mode of action as antimalarials. Acta Haematol 1996; 95: 70-77.
6. Loyevsky M, Lytton SD, Mester B, Libman J, Shanzer A, Cabantchik ZI. The antimalarial action of desferal involves a direct access route to erythrocytic (P. falciparum) parasites. J Clin Invest 1993; 91: 218-224.
7. Golenser J, Tsafack A, Libman J, Amichai I, Shanzer A, Cabantchik ZI. The antimalarial action of hydroxamate-based iron chelators. Effects of drug combinations. Antimicrob Agents Chemother 1995; 39: 61-69.
8. 111In-DFO liposomes. J Control Release 1999; 58: 51-60.
9. Golenser J, Domb A, Teomim D et al. The treatment of animal models of malaria with iron chelators using a novel polymeric device for slow drug release. J Pharmacol Exp Ther 1997; 281: 1127-1135.
10. Golenser J, Miller J, Spira DT, Navok T, Chevion M. Inhibitory effect of a Fava bean component on the in vitro development of P. falciparum in normal and G-6-PD deficient erythrocytes. Blood 1983; 61: 507-510.
11. Sanni LA, Rae C, Maitland A, Stocker R, Hunt NH. Is ischemia involved in the pathogenesis of murine cerebral malaria? Am J Pathol 2001; 159: 1105-1112.
12. Schwarzer E, Kuhn H, Valente E, Arese P. Malaria-parasitized erythrocytes and hemozoin nonenzymatically generate large amounts of hydroxy fatty acids that inhibit monocyte functions. Blood 2003; 101: 722-728.
13. Nathan DG, Weatheralk DJ. Academic freedom in clinical research. N Engl J Med 2002; 347: 1368-1371.
14. Forge A, Li L. Apoptotic death of hair cells in mammalian vestibular sensory epithelia. Hear Res 2000; 139: 97-115.
15. Thuma PE, Mabeza GF, Biemba G et al. Effect of iron chelation therapy on mortality in Zambian children with cerebral malaria. Trans R Soc Trop Med Hyg 1998; 92: 214-218.
16. Mohanty D, Shosh K, Pathare AV, Karnad D. Deferiprone (L1) as an adjuvant therapy for P. falciparum malaria. Indian J Med Res 2002; 115: 17-21.
17. Simonart T, Boelaert JR, Van Hooren JP. Enhancement of classic Kaposi's sarcoma growth after intralesional injections of DFO. Dermatology. 2002; 202: 290-292.
18. Andersen O, Aaseth J. Molecular mechanisms of in vivo metal chelation: implications for clinical treatment of metal intoxications. Environ Health Perspect 2002; 110: 887-890.
19. Liu DY, Liu ZD, Hider RC. Oral iron chelators - development and application. Best Pract Res Clin Haematol 2002; 15: 369-84.
20. Scholz M, Blaheta RA, Henrich D et al. Immunomodulatory properties of the metal chelators desferrioxamine and diethylenetriamine penta-acetic acid in vitro. Transplantation 1996; 62: 1371-1374.
21. Weiss G, Thuma PE, Mabeza G, Werner ER, Herold M, Gordeuk VR. Modulatory potential of iron chelation on nitric oxide formation in cerebral malaria. J Infect Dis 1997; 175: 226-230.
22. Moorman AM, Hossler PA, Meshnick SR. DFO effects on P. falciparum gene expression. Mol Biochem Parasitol 1999; 98: 279-283.
23. Lucas R, Lou J, Morel DR, Ricou B, Suter PM, Grau GE. TNF receptors in the microvascular pathology of acute respiratory distress syndrome and cerebral malaria. J Leukoc Biol 1997; 6: 551-558.
24. Postma NS, Hermsen CC, Crommelin DJ, Zuidema J, Eling WM. Treatment with recombinant human tumour necrosis factor-alpha reduces parasitaemia and prevents Plasmodium berghei K173-induced experimental cerebral malaria in mice. Parasitology 1999; 118: 7-15.
25. Luty AJ, Perkins DJ, Lell B et al. Low interleukin-12 activity in severe Plasmodium falciparum malaria. Infect Immun 2000; 68: 3909-3915.
26. Yang J, Jones SP, Suhara T et al. Endothelial cell overexpression of FasL attenuates ischemia-reperfusion injury in the heart. J Biol Chem 2003; 278: 15185-15191.
27. Yoon G, Kim HJ, Yoon YS, Cho H, Lim IK, Lee JH. Iron chelation-induced senescence-like growth arrest in hepatocyte cell lines: association of transforming growth factor beta1 (TGF-beta1)-mediated p27Kip1 expression. Biochem J 2002; 366: 613-621.
28. Chaston TB, Lovejoy DB, Watts RN, Richardson DR. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311. Clin Cancer Res 2003; 9: 402-414.
29. Prada J, Kremsner PG. Reactive nitrogen intermediates and cerebral malaria. Trans R Soc Trop Med Hyg 1997; 91: 92-93.